Literature DB >> 25017270

An association study of interleukin-4 gene and preeclampsia in Taiwan.

Lin Kang1, Chung-Hwan Chen2, Chen-Hsiang Yu3, Chiung-Hsin Chang4, Fong-Ming Chang5.   

Abstract

OBJECTIVE: To test whether the interleukin-4 (IL-4) gene polymorphisms could be used as markers of susceptibility for preeclampsia in Taiwan.
MATERIALS AND METHODS: This study included 78 women with preeclampsia and 125 normal controls. A polymerase chain reaction was used to analyze the variable number of tandem repeats polymorphism for the IL-4 gene intron 3. Restriction fragment length polymorphism analysis using endonuclease BsmFI was performed for the IL-4 gene at the promoter -590 position. The association between the genotype and disease was examined using Chi-square tests.
RESULTS: We found no significant differences in the genotype distributions and allele frequencies for the IL-4 gene at both promoter and intron 3 regions between the preeclampsia and control groups.
CONCLUSION: Even though this is the first study investigating the association between the promoter region and intron 3 polymorphisms of IL-4 and preeclampsia worldwide, our data do not support a role of the IL-4 gene in the pathogenesis of preeclampsia in Taiwanese women.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Taiwanese; interleukin-4 gene; polymorphism; preeclampsia

Mesh:

Substances:

Year:  2014        PMID: 25017270     DOI: 10.1016/j.tjog.2014.04.017

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  2 in total

1.  PTX3 Gene 3'UTR polymorphism and its interaction with environmental factors are correlated with the risk of preeclampsia in a Chinese Han population.

Authors:  Ning Xu; Wei Zhang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

2.  miR‑320a upregulation contributes to the development of preeclampsia by inhibiting the growth and invasion of trophoblast cells by targeting interleukin 4.

Authors:  Ning Xie; Zhi Jia; Li Li
Journal:  Mol Med Rep       Date:  2019-08-08       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.